Bacillus Probiotic Composition for Consistent IBD Anti-Inflammation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for inflammatory bowel diseases (IBD) such as Crohn's disease, ulcerative colitis, and microscopic colitis have limited efficacy, with many patients experiencing relapses and side effects, and existing probiotic formulations show variable efficacy due to differences in raw materials and culture processes.

Innovation Solution

Incorporating Bacillus amyloliquefaciens and/or Bacillus subtilis into probiotic mixtures at a percentage between 2 and 50% enhances or activates existing probiotic compositions, increasing anti-inflammatory activity and modulating the intestinal immune system.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current therapies (corticosteroids, immunosuppressants, biological drugs) are used to treat IBD, then anti-inflammatory effect is achieved, but patient relapse rate increases and side effects occur

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidside effects and relapse

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent changes the therapeutic parameter from conventional drugs (corticosteroids, immunosuppressants) to probiotic-based therapy using Bacillus amyloliquefaciens and Bacillus subtilis, fundamentally altering the treatment mechanism to achieve anti-inflammatory effects without the harmful side effects and relapse associated with current therapies

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs probiotic bacteria that can be administered orally and transiently colonize the gut to modulate immunity, replacing expensive long-term drug regimens with a more sustainable biological therapy that works through temporary but effective immune system modulation

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Reliability

If existing probiotic formulations are used, then gut microbiota is modulated, but efficacy varies due to differences in raw materials and culture processes

Engineering Contradiction:

Improveprobiotic efficacyVSAvoidcomposition consistency

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent combines two specific bacterial species (Bacillus amyloliquefaciens and Bacillus subtilis) in defined ratios to create a standardized probiotic formulation, merging their complementary functions to achieve consistent and reliable therapeutic effects regardless of variations in raw materials or culture processes

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent specifies precise parameters for the probiotic formulation including the ratio of Bacillus amyloliquefaciens to Bacillus subtilis (from 1:4 to 4:1), the total bacterial count (10^8 to 10^12 CFU/day), and administration conditions, thereby standardizing the composition to ensure consistent efficacy across different production batches

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250345374A1Methods for treating inflammatory bowel disease using bacillus amyloliquefaciens

Publication Date: 2025.11.13 ORMENDES SA

AI summary

This invention relates to the use of Bacillus amyloliquefaciens and/or Bacillus subtilis for the enhancement of active probiotic compositions or for the activation of inactive probiotic compositions for use in the prevention and/or treatment of inflammatory bowel diseases, such as Crohn's disease, ulcerative colitis, indeterminate colitis and microscopic colitis, the compositions thus obtained, and a method for the enhancement of active probiotic compositions or for the activation of inactive probiotic compositions for use in the prevention and/or treatment of inflammatory bowel diseases, such as Crohn's disease, ulcerative colitis, indeterminate colitis and microscopic colitis.